Skip to content
value.today

BioIntelliSense, Inc.

🇺🇸 Golden, Colorado, USAHealth CareFounded 2018
Total raised
$140 M
4 rounds on record
Latest round
$58 M
Dec 2025
First round on record
Dec 2018
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of BioIntelliSense, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2025$58 MNo. 4$50 to $250 million

BioIntelliSense, Inc.: Raise no. 4, Dec 2025

Investors in this round

14 investors had bought by the notice of Jun 4, 2026: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$58 M of $58 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Offering of Preferred Stock and the underlying shares of Common Stock issuable upon conversion of Preferred Stock.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Wang · Executive Officer, Director
  • James Mault · Executive Officer, Director
  • Conlan Ma · Director
  • Xinyaun Yu · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes the issuance of a warrant to purchase preferred stock and the underlying shares of preferred stock upon exercise and the underlying shares of common stock upon conversion.”

Signed by David Wang, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Jun 4, 2026. Read the notice at the SEC.

equitySEC
Apr 2021$45 MNo. 3$10 to $50 million

BioIntelliSense, Inc.: Raise no. 3, Apr 2021

Investors in this round

16 investors had bought by the notice of Sep 15, 2022: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$45 M of $45 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: "Offering of Series B Preferred Stock (""Series B"") and the underlying shares of Common Stock issuable upon conversion of Series B."
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David R. Wang · Executive Officer
  • James R. Mault · Executive Officer, Director
  • Alan R. Meeker · Director
  • John R. Driscoll · Director
  • Lawrence R. Leisure · Director
  • Steve R. Hess · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by James R. Mault, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 15, 2022. Read the notice at the SEC.

equitySEC
Aug 2020$12 MNo. 2$10 to $50 million

BioIntelliSense, Inc.: Raise no. 2, Aug 2020

Investors in this round

11 investors had bought by the notice of Sep 10, 2020: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James Mault · Executive Officer, Director
  • Alan Meeker · Director
  • Larry Leisure · Director
  • Ronald Chwang · Director
  • Steve Hess · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark Adolph, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 10, 2020. Read the notice at the SEC.

equitySEC
Dec 2018$25 MNo. 1$10 to $50 million

BioIntelliSense, Inc.: Raise no. 1, Dec 2018

Investors in this round

22 investors had bought by the notice of Sep 10, 2020: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$25 M of $25 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James Mault · Executive Officer, Director
  • Alan Meeker · Director
  • Larry Leisure · Director
  • Ronald Chwang · Director
  • Steve Hess · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark Adolph, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 10, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • BioIntelliSense, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2026).

    SEC Form D · Jun 2026

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Jun 2026

That is all the official record says: BioIntelliSense, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of BioIntelliSense, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 22 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by BioIntelliSense, Inc.
NameRoleNamed in
David WangExecutive officerJun 2026
James MaultExecutive officerJun 2026
David R. WangExecutive officerSep 2022
James R. MaultExecutive officerSep 2022
Conlan MaDirectorJun 2026
David WangDirectorJun 2026
James MaultDirectorJun 2026
Xinyaun YuDirectorJun 2026
Dawn OwensDirectorDec 2025
Alan R. MeekerDirectorSep 2022
James R. MaultDirectorSep 2022
John R. DriscollDirectorSep 2022
Lawrence R. LeisureDirectorSep 2022
Steve R. HessDirectorSep 2022
Alan MeekerDirectorSep 2020
Larry LeisureDirectorSep 2020
Ronald ChwangDirectorSep 2020
Steve HessDirectorSep 2020